跳至主要内容
临床试验/NCT00274222
NCT00274222终止不适用

The Role of Nebulized Budesonide in the Treatment of Acute Exacerbations of COPD

Inonu University0 个研究点目标入组 120 人开始时间: 2003年1月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
120

研究概览

简要总结

This study was designed to evaluate the hypothesis that nebulized budesonide) might be an alternative to systemic corticosteroids (SC) in the treatment of patients with acute exacerbations of COPD (AECOPD).

详细描述

Patients, hospitalized with AECOPD, were randomized into three groups. Group I received only bronchodilator treatment (BDT), Group II received SC (40 mg prednisolon) plus BDT, and Group III received nebulized budesonide (NB)(1500 mcg qid) plus BDT. Improvement rates in multiple parameters during 10-day hospitalization, and acute exacerbation and re-hospitalization rates within one-month after discharge were compared between the groups.

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • COPD patients who were admitted to our pulmonary department for an acute exacerbation were prospectively enrolled in the study

排除标准

  • COPD patients hospitalized with specific reasons like pneumonia, pulmonary emboli, congestive heart failure, pneumothorax etc. as the cause of acute exacerbation, or patients with risk of imminent respiratory failure requiring mechanical ventilation or direct admission to the ICU were excluded.

研究者

申办方类型
Other

相似试验